The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
The expanding role of prodrugs in contemporary drug design and development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Self-citationStrategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Effective drug delivery by PEGylated drug conjugates
Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00180-1 · Cited by 869
Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization
Kerns, E. H., & Di, L. (2016) · Cited by 784
Self-citationRainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Coexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 649
Self-citationMeanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Self-citationProdrug strategies to overcome poor water solubility
Stella, V. J., & Nti-Addae, K. W. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.013 · Cited by 554
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Li, B., Sedlacek, M., Manoharan, I., Boopathy, R., Duysen, E. G., Masson, P., & Lockridge, O. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.002 · Cited by 540
Prodrugs—from Serendipity to Rational Design
Huttunen, K. M., Raunio, H., & Rautio, J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003459 · Cited by 505
Self-citationEnzyme-Catalyzed Activation of Anticancer Prodrugs
Rooseboom, M., Commandeur, J. N. M., & Vermeulen, N. P. E. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.3 · Cited by 497
Bridging solubility between drug discovery and development
Di, L., Fish, P. V., & Mano, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.007 · Cited by 491
Self-citationProdrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Mortimer, C. G., Wells, G., Crochard, J.-P., Stone, E. L., Bradshaw, T. D., Stevens, M. F. G., & Westwell, A. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050942k · Cited by 475
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
Hauel, N. H., Nar, H., Priepke, H., Ries, U., Stassen, J.-M., & Wienen, W. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0109513 · Cited by 457
Population-Based Mechanistic Prediction of Oral Drug Absorption
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452
The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
Casey Laizure, S., Herring, V., Hu, Z., Witbrodt, K., & Parker, R. B. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1194 · Cited by 446
Polymer therapeutics-prospects for 21st century: The end of the beginning
Duncan, R., & Vicent, M. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.012 · Cited by 412
Chemical Aspects of Selective Toxicity
ALBERT, A. (1958) · Nature · doi:10.1038/182421a0 · Cited by 401
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Ray, A. S., Fordyce, M. W., & Hitchcock, M. J. M. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2015.11.009 · Cited by 392
Clinical Pharmacokinetics of Capecitabine
Reigner, B., Blesch, K., & Weidekamm, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140020-00002 · Cited by 388
Lessons Learned from Marketed and Investigational Prodrugs
Ettmayer, P., Amidon, G. L., Clement, B., & Testa, B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0303812 · Cited by 384
Hosokawa, M. (2008) · Molecules · doi:10.3390/molecules13020412 · Cited by 382
Pharmacokinetics of acyclovir after intravenous and oral administration
de Miranda, P., & Blum, M. R. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.suppl_b.29 · Cited by 381
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase
Sachs, G., Shin, J. M., Briving, C., Wallmark, B., & Hersey, S. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001425 · Cited by 367
Beaumont, K., Webster, R., Gardner, I., & Dack, K. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489253 · Cited by 363
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
Imai, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.173 · Cited by 359
The ProTide Prodrug Technology: From the Concept to the Clinic
Mehellou, Y., Rattan, H. S., & Balzarini, J. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00734 · Cited by 345
Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N. R., Milas, L., & Wallace, S. (1998) · PubMed · Cited by 340
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
Ishikawa, T., Utoh, M., Sawada, N., Nishida, M., Fukase, Y., Sekiguchi, F., & Ishitsuka, H. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00682-5 · Cited by 325
Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., & Posner, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2759 · Cited by 315
Transport of Valganciclovir, a Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2
Sugawara, M., Huang, W., Fei, Y., Leibach, F. H., Ganapathy, V., & Ganapathy, M. E. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200006)89:6<781::aid-jps10>3.0.co;2-7 · Cited by 312
Seymour (2009) · International Journal of Oncology · doi:10.3892/ijo_00000293 · Cited by 304
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
Murakami, E., Tolstykh, T., Bao, H., Niu, C., Steuer, H. M. M., Bao, D., Chang, W., Espiritu, C., Bansal, S., Lam, A. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.161802 · Cited by 291
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012) · Journal of Drug Delivery · doi:10.1155/2012/103973 · Cited by 282
Shi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., Li, Y., Akhlaghi, F., & Yan, B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111807 · Cited by 279
Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Drückes, P., Esser, N., Drevs, J., Rognan, D., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020276c · Cited by 275
Oseltamivir: A Review of its Use in Influenza
McClellan, K., & Perry, C. M. (2001) · Drugs · doi:10.2165/00003495-200161020-00011 · Cited by 257
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization
Lee, W. A., Gu, L., Miksztal, A. R., Chu, N., Leung, K., & Nelson, P. H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015828802490 · Cited by 254
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Grigoriadis, D. E., Smith, E., Hoare, S. R. J., Madan, A., & Bozigian, H. P. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239160 · Cited by 253
Patterson, A. V., Ferry, D. M., Edmunds, S. J., Gu, Y., Singleton, R. S., Patel, K., Pullen, S. M., Hicks, K. O., Syddall, S. P., Atwell, G. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0478 · Cited by 250
Kirby, B. J., Symonds, W. T., Kearney, B. P., & Mathias, A. A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0261-7 · Cited by 241
Soft drug design: General principles and recent applications
Bodor, N., & Buchwald, P. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x · Cited by 239
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Self-citationNaumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., DePasquale, S. E., Nowara, E., Gilbert, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7685 · Cited by 238
Li, W., Escarpe, P. A., Eisenberg, E. J., Cundy, K. C., Sweet, C., Jakeman, K. J., Merson, J., Lew, W., Williams, M., Zhang, L., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.647 · Cited by 223
Linenberger, M. L. (2005) · Leukemia · doi:10.1038/sj.leu.2403598 · Cited by 214
Balimane, P. V., Tamai, I., Guo, A., Nakanishi, T., Kitada, H., Leibach, F. H., Tsuji, A., & Sinko, P. J. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9298 · Cited by 214
Rademaker-Lakhai, J. M., Terret, C., Howell, S. B., Baud, C. M., de Boer, R. F., Pluim, D., Beijnen, J. H., Schellens, J. H. M., & Droz, J.-P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0315 · Cited by 214
Talley, J. J., Bertenshaw, S. R., Brown, D. L., Carter, J. S., Graneto, M. J., Kellogg, M. S., Koboldt, C. M., Yuan, J., Zhang, Y. Y., & Seibert, K. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000069h · Cited by 213
Minton, N. P. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro777 · Cited by 192
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 189
Textbook of Drug Design and Discovery
(2016) · CRC Press eBooks · doi:10.1201/9781315371818 · Cited by 175
Bräuer, A., Grubert, L. S., Roll, W., Schrader, A. J., Schäfers, M., Bögemann, M., & Rahbar, K. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3751-z · Cited by 173
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170
Schmitt-Hoffmann, A., Roos, B., Heep, M., Schleimer, M., Weidekamm, E., Brown, T., Roehrle, M., & Beglinger, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.279-285.2006 · Cited by 170
Singer, J. W., Baker, B., de Vries, P., Kumar, A., Shaffer, S., Vawter, E., Bolton, M., & Garzone, P. D. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47932-x_6 · Cited by 168
Evidence-based approach to assess passive diffusion and carrier-mediated drug transport
Di, L., Artursson, P., Avdeef, A., Ecker, G. F., Faller, B., Fischer, H., Houston, J. B., Kansy, M., Kerns, E. H., Krämer, S. D., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.015 · Cited by 167
Self-citationErion, M. D., Reddy, K. R., Boyer, S. H., Matelich, M. C., Gomez-Galeno, J., Lemus, R. H., Ugarkar, B. G., Colby, T. J., Schanzer, J., & van Poelje, P. D. (2004) · Journal of the American Chemical Society · doi:10.1021/ja031818y · Cited by 165
Gene-Directed Enzyme Prodrug Therapy
Zhang, J., Kale, V. M., & Chen, M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9675-7 · Cited by 163
Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600517 · Cited by 163
Enzyme-mediated hydrolytic activation of prodrugs
Yang, Y.-H., Aloysius, H., Inoyama, D., Chen, Y., & Hu, L.-Q. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.08.001 · Cited by 162
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
De Clercq, E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.04.015 · Cited by 162
Profiling Cytochrome P 450 Expression in Ovarian Cancer: Identification of Prognostic Markers
Downie, D., McFadyen, M. C. E., Rooney, P. H., Cruickshank, M. E., Parkin, D. E., Miller, I. D., Telfer, C., Melvin, W. T., & Murray, G. I. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0466 · Cited by 161
Cytochrome P450-Activated Prodrugs
Ortiz de Montellano, P. R. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.197 · Cited by 161
Liu, Q., Yang, Q., Sun, W., Vogel, P., Heydorn, W. E., Yu, X.-Q., Hu, Z., Yu, W., Jonas, B., Pineda, R., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132670 · Cited by 156
Prodrugs : challenges and rewards
Stella, V. J. (2007) · Cited by 153
Ślusarczyk, M., Lopez, M. H., Balzarini, J. M., Mason, M. D., Jiang, W. G., Blagden, S. P., Thompson, E., Ghazaly, E. A., & McGuigan, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401853a · Cited by 153
Cundy, K. C., Branch, R., Chernov-Rogan, T., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067934 · Cited by 152
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients
Nutt, J. G., & Woodward, W. R. (1986) · Neurology · doi:10.1212/wnl.36.6.739 · Cited by 149
Ishikawa, T., Matsunaga, N., TAWADA, H., Kuroda, N., Nakayama, Y., Ishibashi, Y., TOMIMOTO, M., Ikeda, Y., Tagawa, Y., Iizawa, Y., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00126-3 · Cited by 147
Amino acids as promoieties in prodrug design and development
Vig, B. S., Huttunen, K. M., Laine, K., & Rautio, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.001 · Cited by 146
Self-citationSanghani, S. P., Quinney, S. K., Fredenburg, T. B., Davis, W. I., Murry, D. J., & BOSRON, W. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.505 · Cited by 145
Meanwell, N. A., Krystal, M., Nowicka-Sans, B., Langley, D. R., Conlon, D. A., Eastgate, M. D., Grasela, D. M., Timmins, P., Wang, T., & Kadow, J. F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01337 · Cited by 145
Self-citationHatanaka, T., Haramura, M., Fei, Y.-J., Miyauchi, S., Bridges, C. C., Ganapathy, P. S., Smith, S. B., Ganapathy, V., & Ganapathy, M. E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057109 · Cited by 142
Schmitt‐Hoffmann, A. H., Roos, B., Maares, J., Heep, M., Spickermann, J., Weidekamm, E., Brown, T., & Roehrle, M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.286-293.2006 · Cited by 141
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Linker, R. A., & Haghikia, A. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316653307 · Cited by 139
Cheer, S. M., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161080-00010 · Cited by 138
Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations
Sharma, S. K., & Bagshawe, K. D. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.009 · Cited by 137
Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man
Brass, E. P. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.589 · Cited by 136
Prodrug strategy for cancer cell-specific targeting: A recent overview
Zhang, X., Li, X., You, Q., & Zhang, X. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.010 · Cited by 135
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
Azad-Khan, A., Truelove, S. C., & Aronson, J. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01415.x · Cited by 133
O’Brien, C. F., Jimenez, R., Hauser, R. A., Factor, S. A., Burke, J., Mandri, D., & Castro‐Gayol, J. C. (2015) · Movement Disorders · doi:10.1002/mds.26330 · Cited by 133
Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Wilkinson, S. R., Bot, C., Kelly, J. M., & Hall, B. S. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796575894 · Cited by 133
Rowinsky, E. K., Rizzo, J. D., Ochoa, L., Takimoto, C. H. M., Forouzesh, B., Schwartz, G. H., Hammond, L. A., Patnaik, A., Kwiatek, J., Goetz, A. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.143 · Cited by 132
Stella, V. J., Tilley, J., Oliyai, R., Maag, H., Hageman, M. J., & Borchardt, R. T. (2007) · Springer eBooks · doi:10.1007/978-0-387-49785-3 · Cited by 131
Self-citationBrentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0705-5 · Cited by 128
Wire, M. B., Shelton, M. J., & Studenberg, S. D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00002 · Cited by 127
Jana, S., Mandlekar, S., & Marathe, P. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793205426 · Cited by 127
Prodrugs: Some Thoughts and Current Issues
Stella, V. J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22205 · Cited by 126
O'Brien, M. E. R., Socinski, M. A., Popovich, A. Y., Bondarenko, I., Tomova, A., ̆ı, B. T. B., Hotko, Y., Ganul, V. L., Kostinsky, I. Y., Eisenfeld, A. J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b68 · Cited by 125
Cundy, K. C., Annamalai, T., Bu, L., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067959 · Cited by 121
Drug transport via the intestinal peptide transporter PepT1
Brandsch, M. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.004 · Cited by 119
Liver-Targeted Drug Delivery Using HepDirect Prodrugs
Erion, M. D., van Poelje, P. D., MacKenna, D. A., Colby, T. J., Montag, A. C., Fujitaki, J. M., Linemeyer, D. L., & Bullough, D. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075903 · Cited by 119
Clinical pharmacology of polyethylene glycol-L-asparaginase.
Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
Karlgren, M., Gomez, A. V., Stark, K., Svärd, J., Rodríguez‐Antona, C., Oliw, E. H., Bernal, M. L., y Cajal, S. R., Johansson, I., & Ingelman‐Sundberg, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.200 · Cited by 115
Proteases in cancer drug delivery
Vandooren, J., Opdenakker, G., Loadman, P. M., & Edwards, D. R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.020 · Cited by 114
Michel, M. C. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1787 · Cited by 110
Gillis, J. C., & Wiseman, L. R. (1996) · Drugs · doi:10.2165/00003495-199651040-00007 · Cited by 110
Antibody–Drug Conjugates for Cancer Therapy
Parslow, A. C., Parakh, S., Lee, F.-T., Gan, H. K., & Scott, A. M. (2016) · Biomedicines · doi:10.3390/biomedicines4030014 · Cited by 110
Adachi, K., & Chiba, K. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100002 · Cited by 108
CYP2D6 polymorphisms and the impact on tamoxifen therapy
Beverage, J. N., Sissung, T. M., Sion, A. M., et al. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20892 · Cited by 105
Shaffer, S. A., Baker-Lee, C., Kennedy, J., Lai, M. S., de Vries, P. W., Buhler, K. R., & Singer, J. W. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0296-4 · Cited by 104
Your Prodrug Releases Formaldehyde: Should You Be Concerned? No!
Dhareshwar, S. S., & Stella, V. J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21319 · Cited by 103
Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanová, P., & Kopec̆ek, J. (1982) · Bioscience Reports · doi:10.1007/bf01122173 · Cited by 101
Glutathione-S-transferase Activates Novel Alkylating Agents
Lyttle, M. H., Satyam, A., Hocker, M. D., Bauer, K. E., Caldwell, C. G., Hui, H. C., Morgan, A. S., Mergia, A., & Kauvar, L. M. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00036a016 · Cited by 100
L‐Dihydroxyphenylserine (L‐DOPS): A Norepinephrine Prodrug
Goldstein, D. S. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00189.x · Cited by 99
Furfine, E. S., Baker, C. T., Hale, M. R., Reynolds, D. J., Salisbury, J. A., Searle, A. D., Studenberg, S. D., Todd, D., Tung, R. D., & Spaltenstein, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.791-798.2004 · Cited by 98
Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis
Laizure, S. C., Parker, R. B., Herring, V. L., & Hu, Z. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054353 · Cited by 98
Phosphorylated Morpholine Acetal Human Neurokinin-1 Receptor Antagonists as Water-Soluble Prodrugs
Hale, J. J., Mills, S. G., MacCoss, M., Dorn, C. P., Finke, P. E., Budhu, R. J., Reamer, R. A., Huskey, S.-E. W., Luffer, D. R., Dean, B. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990617v · Cited by 96
Satchi‐Fainaro, R., Hailu, H., Davies, J. W., Summerford, C., & Duncan, R. (2003) · Bioconjugate Chemistry · doi:10.1021/bc020091k · Cited by 94
Tunek, A., & Svensson, L.-Å. (1988) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07050-3 · Cited by 93
Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor
Dobesh, P. P. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.9.1089 · Cited by 91
Stella, V. J. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.3.277 · Cited by 87
Prodrugs – Recent approvals and a glimpse of the pipeline
(2017) · doi:10.1016/j.ejps.2017.08.002 · Cited by 86
Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole
Ohwada, J., Tsukazaki, M., Hayase, T., Oikawa, N., Isshiki, Y., Fukuda, H., Mizuguchi, E., Sakaitani, M., Shiratori, Y., Yamazaki, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00892-2 · Cited by 84
Thomson, A. H., Vasey, P. A., Murray, L. S., Cassidy, J., Fraier, D., Frigerio, E., & Twelves, C. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690657 · Cited by 81
Birkuš, G., Bam, R. A., Willkom, M., Frey, C. R., Tsai, L. K., Stray, K. M., Yant, S. R., & Cihlář, T. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01834-15 · Cited by 80
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Kurtz, T. W., Kajiya, & Kurtz (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22595 · Cited by 79
Absorption Rate Limit Considerations for Oral Phosphate Prodrugs
Heimbach, T., Oh, D.-M., Li, L. Y., Forsberg, M., Savolainen, J., Leppänen, J., Matsunaga, Y., Flynn, G. L., & Fleisher, D. (2003) · Pharmaceutical Research · doi:10.1023/a:1023827017224 · Cited by 79
Chemistry-enabled drug delivery (prodrugs): recent progress and challenges
Clas, S., Sánchez, R. I., & Nofsinger, R. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.08.014 · Cited by 76
Nishimuta, H., Houston, J. B., & Galetin, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057372 · Cited by 75
The Discovery of Dabigatran Etexilate
van Ryn, J., Goss, A., Hauel, N. H., Wienen, W., Priepke, H. W. M., Nar, H., & Clemens, A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00012 · Cited by 75
Rivera, S. P., Wang, F., Saarikoski, S. T., Taylor, R. T., Chapman, B., Zhang, R., & Hankinson, O. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609617200 · Cited by 73
The design and bioactivation of presystemically stable prodrugs
Svensson, L.-Å., & Tunek, A. (1988) · Drug Metabolism Reviews · doi:10.3109/03602538809049622 · Cited by 73
Williams, E. T., Bacon, J. A., Bender, D. M., Lowinger, J. J., Guo, W., Ehsani, M. E., Wang, X., Wang, H., Qian, Y., Ruterbories, K. J., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041335 · Cited by 72
Tan, B. S., Tiong, K. H., Muruhadas, A., Randhawa, N., Choo, H. L., Bradshaw, T. D., Stevens, M. F. G., & Leong, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0391 · Cited by 67
Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery
Gobeau, N., Stringer, R., De Buck, S., Tuntland, T., & Faller, B. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1951-z · Cited by 67
Bueno, A. B., Collado, I., de Dios, A., Domínguez, C., Martín, J. A., Martín, L. M., MARTINEZ‐GRAU, A., Montero, C., Pedregal, C., Catlow, J. T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050235r · Cited by 65
Möllmann, H., Hochhaus, G., Rohatagi, S., Barth, J., & Derendorf, H. (1995) · Pharmaceutical Research · doi:10.1023/a:1016287104656 · Cited by 62
Garrett, C. R., Bekaii‐Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., Kavan, P., Shacham‐Shmueli, E., Buchbinder, A., & Goldberg, R. M. (2013) · Cancer · doi:10.1002/cncr.28358 · Cited by 62
Tsuda, M., Terada, T., Irie, M., Katsura, T., Niida, A., Tomita, K., Fujii, N., & Inui, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102830 · Cited by 61
Oseltamivir: a clinical and pharmacological perspective
Aoki, F. Y., & Doucette, K. E. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.10.1671 · Cited by 60
Kinetics of methylprednisolone and its hemisuccinate ester
Derendorf, H., Möllmann, H., Rohdewald, P. J., et al. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.79 · Cited by 59
Bruderer, S., Hurst, N., Kaufmann, P., & Dingemanse, J. (2014) · Pharmacology · doi:10.1159/000367630 · Cited by 58
Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery
Heimbach, T., Fleisher, D., & Kaddoumi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-49785-3_5 · Cited by 57
Brown, J. L., Chien, C., Timmins, P., Dennis, A. B., Doll, W. J., Sandefer, E. P., Page, R., Nettles, R. E., Zhu, L., & Grasela, D. M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23476 · Cited by 57
Mutual pro-drugs of .BETA.-lactam antibiotics and .BETA.-lactamase inhibitors.
Baltzer, B., Binderup, E., von Daehne, W., Godtfredsen, W. O., HANSEN, K., Nielsen, B., SORENSEN, H., & Vangedal, S. (1980) · The Journal of Antibiotics · doi:10.7164/antibiotics.33.1183 · Cited by 57
Targeted Delivery of Small and Macromolecular Drugs
Narang, A. S., & Mahato, R. I. (2010) · CRC Press eBooks · doi:10.1201/9781420087734 · Cited by 57
Djebli, N., Fabre, D., Boulenc, X., Fabre, G., Sultan, E., & Hurbin, F. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062596 · Cited by 56
Reaction phenotyping to assess victim drug-drug interaction risks
Di, L. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1367280 · Cited by 55
Self-citationMelanocyte-Directed enzyme prodrug therapy (MDEPT)
Jordan, A. M., Khan, T. H., Malkin, H., Osborn, H. M. I., Photiou, A., & Riley, P. A. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00039-6 · Cited by 53
Tirapazamine: laboratory data relevant to clinical activity.
Brown, J. M., & Lh, W. (1998) · PubMed · Cited by 53
Brantley, E. J., Trapani, V., Alley, M. C., Hose, C. D., Bradshaw, T. D., Stevens, M. F. G., Sausville, E. A., & Stinson, S. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001057 · Cited by 52
Glutathione Transferase (GST)-Activated Prodrugs
Ruzza, P., & Calderan, A. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5020220 · Cited by 51
Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination
Sharma, S. K., & Bagshawe, K. D. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1247802 · Cited by 51
Kadow, J. F., Ueda, Y., Meanwell, N. A., Connolly, T. P., Wang, T., Chen, C., Yeung, K., Zhu, J., Bender, J. A., Yang, Z. D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201218m · Cited by 49
Self-citationGlucuronides in Anti-Cancer Therapy
Chen, X., Wu, B., & Wang, P. G. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033353470 · Cited by 48
Proteases as activators for cytotoxic prodrugs in antitumor therapy.
Weidle, U. H., Tiefenthaler, G., & Georges, G. J. (2014) · PubMed · Cited by 48
The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Kane, S. V., & Bjorkman, D. J. (2003) · PubMed · Cited by 47
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Garcia, G. A., Ngai, P., Mosaed, S., & Lin, K. (2016) · Clinical ophthalmology · doi:10.2147/opth.s103985 · Cited by 46
Prodrugs and Targeted Delivery
(2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633166 · Cited by 45
Bentley, A., Butters, M., Green, S. P., Learmonth, W. J., MacRae, J., Morland, M. C., O'Conno, G., & Skuse, J. (2001) · Organic Process Research & Development · doi:10.1021/op010064+ · Cited by 44
Midodrine: a selective α-adrenergic agonist for orthostatic hypotension and dialysis hypotension
Cruz, D. N. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.835 · Cited by 44
The codrug approach for facilitating drug delivery and bioactivity
Aljuffali, I. A., Lin, C., Chen, C., & Fang, J. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1187598 · Cited by 43
Stella, V. J., Martodihardjo, S., Terada, K., & Rao, V. M. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980008v · Cited by 41
Fenton, C., & Perry, C. M. (2005) · Drugs · doi:10.2165/00003495-200565160-00014 · Cited by 39
Lukacova, V., Goelzer, P., Reddy, M. B., Greig, G., Reigner, B. G., & Parrott, N. J. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9956-4 · Cited by 39
Scomparin, A., Florindo, H. F., Tiram, G., Ferguson, E. L., & Satchi‐Fainaro, R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.011 · Cited by 39
Perkins, E. J., & Abraham, T. L. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016154 · Cited by 35
Bailey, S. M., Lewis, A. D., Knox, R. J., Patterson, L. H., Fisher, G. R., & Workman, P. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00661-8 · Cited by 32
Lisdexamfetamine: A pharmacokinetic review
Comiran, E., Kessler, F. H., Fröehlich, P. E., & Limberger, R. P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.026 · Cited by 31
Matsuda, Y., Konno, Y., Hashimoto, T., Nagai, M., Taguchi, T., Satsukawa, M., & Yamashita, S. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1489-x · Cited by 28
One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients
Persson, G., Baas, A., Knight, A. K., Larsen, B., & Olsson, H. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08010034 · Cited by 28
Recent advances in macromolecular prodrugs
Frich, C. K., & Zelikin, A. N. (2017) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2017.06.002 · Cited by 28
Hu, Z.-Y., Edginton, A. N., Laizure, S. C., & Parker, R. B. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0160-3 · Cited by 26
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes
Xu, H., Majmudar, J. D., Davda, D., Ghanakota, P., Kim, K. H., Carlson, H. A., Showalter, H. D., Martin, B. R., & Amidon, G. L. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00414 · Cited by 25
Biological conversion of aripiprazole lauroxil − An N-acyloxymethyl aripiprazole prodrug
Rohde, M., M∅rk, N., Håkansson, A. E., et al. (2014) · Results in Pharma Sciences · doi:10.1016/j.rinphs.2014.04.002 · Cited by 25
Bimatoprost: A Review of its Use in Open-Angle Glaucoma and Ocular Hypertension
Curran, M. P. (2009) · Drugs & Aging · doi:10.2165/11203210-000000000-00000 · Cited by 23
Malmborg, J., & Ploeger, B. A. (2012) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2012.12.002 · Cited by 22
Yan, G. Z., Generaux, C., Yoon, M., Goldsmith, R. B., Tidwell, R. R., Hall, J. E., Olson, C. A., M.A., H. J. C. I., Brouwer, K. L. R., & Paine, M. F. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040063 · Cited by 22
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Najib, J., Wimer, D., Zeng, J., Lam, K. W., Romanyak, N., Paige Morgan, E., & Thadavila, A. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517728090 · Cited by 17
Trapa, P. E., Beaumont, K. C., Atkinson, K. A., Eng, H. F., King‐Ahmad, A., Scott, D. O., Maurer, T. S., & Di, L. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.001 · Cited by 11
Self-citationProdrugs Designed to Target Transporters for Oral Drug Delivery
Warren, M. S., & Rautio, J. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633166.ch6 · Cited by 5
Self-citationThe Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs
Bai, J. P. F., Pacanowski, M., Rahman, A., & Lesko, L. L. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633166.ch16 · Cited by 2
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Molecular photoswitches in aqueous environments
Volarić, J., Szymanski, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 438
Ertl, P., Altmann, E., & McKenna, J. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00754 · Cited by 429
Metadata
- Authors
- Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-04-27
- Volume
- 17
- Issue
- 8
- Pages
- 559-587
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2801859295
- Cited by
- 767
- References
- 191
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.